Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Twist Bioscience Corporation (TWST:NASDAQ), powered by AI.
Twist Bioscience Corporation is currently trading at $84.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Twist Bioscience Corporation on Alpha Lenz.
Twist Bioscience Corporation's P/E ratio is -65.4.
“Twist Bioscience Corporation trades at a P/E of -65.4 (undervalued) with modest ROE of -16.4%. 3Y revenue CAGR of 22.8% highlights clear growth momentum.”
Ask for details →Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.
“Twist Bioscience Corporation trades at a P/E of -65.4 (undervalued) with modest ROE of -16.4%. 3Y revenue CAGR of 22.8% highlights clear growth momentum.”
Ask for details →Twist Bioscience Corporation (ticker: TWST) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 923 employees. Market cap is $5.1B.
The current price is $84.95 with a P/E ratio of -65.41x and P/B of 10.74x.
ROE is -16.43% and operating margin is -36.18%. Annual revenue is $377M.